(Q30789784)

English

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 June 2017

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial (English)

1 reference

Europe PubMed Central

26 June 2017

phase III clinical trial

0 references

0 references

relapsing-remitting multiple sclerosis

0 references

multiple sclerosis

0 references

Philipp von Rosenstiel

13

object named as

Philipp von Rosenstiel

1 reference

Europe PubMed Central

26 June 2017

9

object named as

Ludwig Kappos

1 reference

Europe PubMed Central

26 June 2017

Peter Calabresi

1

object named as

Peter A Calabresi

1 reference

Europe PubMed Central

26 June 2017

Ernst-Wilhelm Radue

2

object named as

Ernst-Wilhelm Radue

1 reference

Europe PubMed Central

26 June 2017

10

object named as

Tracy Stites

1 reference

Europe PubMed Central

26 June 2017

Kottil W Rammohan

5

object named as

Kottil W Rammohan

1 reference

Europe PubMed Central

26 June 2017

14

object named as

Fred D Lublin

1 reference

Europe PubMed Central

26 June 2017

author name string

Douglas Goodin

3

1 reference

Europe PubMed Central

26 June 2017

Douglas Jeffery

4

1 reference

Europe PubMed Central

26 June 2017

Anthony T Reder

6

1 reference

Europe PubMed Central

26 June 2017

Timothy Vollmer

7

1 reference

Europe PubMed Central

26 June 2017

Mark A Agius

8

1 reference

Europe PubMed Central

26 June 2017

Bingbing Li

11

1 reference

Europe PubMed Central

26 June 2017

Linda Cappiello

12

1 reference

Europe PubMed Central

26 June 2017

publication date

28 March 2014

1 reference

Europe PubMed Central

26 June 2017

Lancet Neurology

1 reference

Europe PubMed Central

26 June 2017

13

1 reference

Europe PubMed Central

26 June 2017

6

1 reference

Europe PubMed Central

26 June 2017

545-556

1 reference

Europe PubMed Central

26 June 2017

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970049-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970049-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970049-3

7 January 2021

based on heuristic

inferred from DOI database lookup

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970049-3

7 January 2021

based on heuristic

inferred from DOI database lookup

FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970049-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970049-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970049-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970049-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970049-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970049-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessing disability progression with the Multiple Sclerosis Functional Composite

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970049-3

7 January 2021

based on heuristic

inferred from DOI database lookup

EDSS variability before randomization may limit treatment discovery in primary progressive MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970049-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study combining interferon and glatiramer acetate in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970049-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(14)70049-3

1 reference

Europe PubMed Central

26 June 2017

1 reference

Europe PubMed Central

26 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30789784&oldid=1959004702"